Imperial Announces New Family of Companies Including Exclusive Life-Science Translation Provider
PHILADELPHIA (June 25, 2012)--The life-science industry's largest tradeshow, the 48th Annual DIA, is the backdrop for today's debut of the new "Imperial Family of Companies" comprising DAC Patient Recruitment Services, Imperial Graphics and ClinicaLingua Translation Services--three vertically integrated brands which provide Pharma/Biotech/Devices with true service synergy. Executives of Imperial, a 40-year veteran in the clinical research space, tout the new family model for its ability to help clients save time, maximize resources and minimize risk by offering the strength of three companies, with the simplicity and convenience of one point of contact.
Of particular note, the addition of ClinicaLingua fills a void for clients challenged with ensuring accurate and appropriate translations for physician and patient audiences, coordinating communication and file management on a global scale, while managing complexities in the translation of all study and recruitment materials.
"Both announcements are pivotal to our organization," said Matthew Bissell, CEO of Imperial. "We have undergone a lot of positive change and growth that needs to be communicated to our clients and the industry as a whole. The 'Family of Companies' model with common ownership and management helps us position that message."
ClinicaLingua's infrastructure and team complement Imperial's already growing translation services segment. "Our skillset, clinical focus and ISO-certified standards tie-in well to the strategic vision of the Imperial organization," stated Scott Van Til, manager at ClinicaLingua.
DAC Patient Recruitment Services (formerly D. Anderson & Company) offers strategic site selection, country-customized patient recruitment and retention, award-winning creative services, and CEU-certified global clinical staff training. A trusted brand in the life-sciences industry for over four decades, Imperial Graphics provides high-end design and printing of site materials, custom kit production, fulfillment, global logistics, and electronic site closure services.
On location at DIA this week, Steve Swanson, president and COO of Imperial, said: "Imperial is a highly specialized functional service provider (FSP). Historical FSP models rely on an aggregated group of suppliers that forces project managers to expend unnecessary effort and time to deal with different vendors and dissimilar business systems. The ownership versus partnership found within our model offers compatible business systems, consolidated contracts, and the model-wide goal congruence necessary to drive tangible efficiencies. We are one of the few, if not the only firm, in the clinical trial space with this type of specialized integration. Our businesses are 100 percent focused on the clinical space, unlike others where it is only one of their business segments."
Since its founding in 1945, Imperial has become one of the world's premier support organizations for sponsors and CROs. As Bissell concluded, "We have been in this business longer than most, and have seen significant transitions take place. Throughout these transitions, Imperial has remained committed to innovation and change in order to exceed our customers' needs and expectations. Today's announcements reinforce that commitment."
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.